Trial comparisons

curl "https://conductscience.org/api/comparisons/v1?page=173"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=173

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01146652-deaths",
        "title": "Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) vs Sarilumab Monotherapy: deaths from any cause",
        "summary": "49 of 1910 against 3 of 111; risk difference -0.1 points, 95% interval -5.1 to 1.8; NCT01146652, Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)",
        "record": "/library/comparisons/NCT01146652-deaths",
        "nct_id": "NCT01146652",
        "kind": "deaths",
        "participants": 2021,
        "risk_difference": {
          "value": -0.0013725767652469252,
          "lower": -0.05119458953826203,
          "upper": 0.01817734717742504
        },
        "group_1": "49 of 1,910",
        "group_2": "3 of 111",
        "difference": "-0.1 points",
        "interval": "-5.1 to 1.8",
        "trial_title": "Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)"
      },
      {
        "id": "NCT01146652-sae",
        "title": "Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD) vs Sarilumab Monotherapy: serious adverse events",
        "summary": "617 of 1910 against 27 of 111; risk difference 8.0 points, 95% interval -1.0 to 15.3; NCT01146652, Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)",
        "record": "/library/comparisons/NCT01146652-sae",
        "nct_id": "NCT01146652",
        "kind": "serious-adverse-events",
        "participants": 2021,
        "risk_difference": {
          "value": 0.07979340597141643,
          "lower": -0.010123835602008358,
          "upper": 0.15329885689566633
        },
        "group_1": "617 of 1,910",
        "group_2": "27 of 111",
        "difference": "8.0 points",
        "interval": "-1.0 to 15.3",
        "trial_title": "Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=174",
  "request_id": "KoadtV-sEf7p6QFu"
}